Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404742 · ClinicalTrials.gov registry record · Phase 3
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
A Phase 3 study, sponsored by Lux Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
NCT00404742 is a Phase 3 study that has completed, run by Lux Biosciences. The registered enrollment target is 232 participants.
The verdict
NCT00404742, a Phase 3 study, has completed, sponsored by Lux Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
Interventions
- DRUG Placebo
- DRUG LX211
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404742
The ClinicalTrials.gov registry entry for NCT00404742 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lux Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00404742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00404742 about?
NCT00404742 is a clinical study titled "A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis". The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
What is the current status of trial NCT00404742?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2007-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00404742?
The interventions under investigation include: Placebo (DRUG), LX211 (DRUG).
Who is sponsoring clinical trial NCT00404742?
This trial is sponsored by Lux Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.